Filing Details
- Accession Number:
- 0000914475-24-000007
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-01-04 18:32:49
- Reporting Period:
- 2024-01-02
- Accepted Time:
- 2024-01-04 18:32:49
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 914475 | Neurocrine Biosciences Inc | NBIX | Biological Products, (No Disgnostic Substances) (2836) | 330525145 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1567160 | Kyle Gano | 12780 El Camino Real San Diego CA 92130 | Chief Business Development Off | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-01-02 | 68,884 | $19.59 | 199,134 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-01-02 | 68,884 | $131.47 | 130,250 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-01-02 | 6,116 | $19.59 | 136,366 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-01-02 | 6,116 | $131.44 | 130,250 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option | Disposition | 2024-01-02 | 68,884 | $19.59 | 68,884 | $19.59 |
| Common Stock | Incentive Stock Option | Disposition | 2024-01-02 | 6,116 | $19.59 | 6,116 | $19.59 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2024-01-16 | No | 4 | M | Direct | |
| 0 | 2024-01-16 | No | 4 | M | Direct |
Footnotes
- The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $130.76 to $133.33. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $130.76 to $133.27. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The option was granted January 16, 2014 and vested in 48 equal monthly installments beginning February 16, 2014. These options will expire ten years from the date of grant on January 16, 2024.
Billionaire Hedge Funds
